Should I buy or sell Inovio Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" INO shares. View INO analyst ratings or view top-rated stocks .

What is Inovio Pharmaceuticals' stock price target for 2024?

3 Wall Street research analysts have issued 1-year price targets for Inovio Pharmaceuticals' stock. Their INO share price targets range from $4.00 to $24.00. On average, they anticipate the company's share price to reach $13.33 in the next twelve months. This suggests a possible upside of 97.8% from the stock's current price. View analysts price targets for INO or view top-rated stocks among Wall Street analysts .

How have INO shares performed in 2024?

Inovio Pharmaceuticals' stock was trading at $6.12 at the beginning of 2024. Since then, INO stock has increased by 10.1% and is now trading at $6.74. View the best growth stocks for 2024 here .

When is Inovio Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024. View our INO earnings forecast .

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) released its quarterly earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, beating the consensus estimate of ($1.68) by $0.12. The biopharmaceutical company had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.20 million. Inovio Pharmaceuticals had a negative trailing twelve-month return on equity of 84.52% and a negative net margin of 19,271.31%. During the same period in the previous year, the business posted ($5.52) earnings per share.

When did Inovio Pharmaceuticals' stock split?

Inovio Pharmaceuticals's stock reverse split before market open on Thursday, January 25th 2024. The 1-12 reverse split was announced on Thursday, January 25th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is J. Joseph Kim's approval rating as Inovio Pharmaceuticals' CEO?

12 employees have rated Inovio Pharmaceuticals Chief Executive Officer J. Joseph Kim on Glassdoor.com . J. Joseph Kim has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Inovio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX) , Moderna (MRNA) , Gilead Sciences (GILD) , NVIDIA (NVDA) , Advanced Micro Devices (AMD) , Tesla (TSLA) , Pfizer (PFE) , Micron Technology (MU) , Sorrento Therapeutics (SRNE) and Vaxart (VXRT) .

Who are Inovio Pharmaceuticals' major shareholders?

Inovio Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Green Alpha Advisors LLC (0.17%), Keystone Financial Group (0.54%), Vanguard Personalized Indexing Management LLC (0.51%), Principal Financial Group Inc. (0.30%), Simplex Trading LLC (0.00%) and Wolverine Asset Management LLC (0.00%). Insiders that own company stock include David B Weiner, David B Weiner , Jacqueline Elizabeth Shea , Laurent Humeau , Lota S Zoth , Peter Kies and Simon X Benito . View institutional ownership trends .

How do I buy shares of Inovio Pharmaceuticals?

Shares of INO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:INO

Inovio Pharmaceuticals (INO) Stock Price, News & Analysis

$6.74

+1.00 (+17.42%)

(As of 02/9/2024 08:56 PM ET)

Compare

Today's Range: $5.91
▼
$6.79
50-Day Range: $4.36
▼
$10.62
52-Week Range: $3.89
▼
$19.32

Volume: 705,200 shs
Average Volume: 558,828 shs
Market Capitalization: $153.27 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.33

Get Inovio Pharmaceuticals alerts:

Inovio Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 97.8% Upside
$13.33 Price Target
Short Interest: Healthy
98.99% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.84
Upright™ Environmental Score
News Sentiment: 0.37
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($5.80) to ($3.89) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.99 out of 5 stars

Medical Sector

213th out of 922 stocks

Surgical & Medical Instruments Industry

25th out of 92 stocks

3.3

Analyst's Opinion

Consensus Rating
Inovio Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.33, Inovio Pharmaceuticals has a forecasted upside of 97.8% from its current price of $6.74.
Amount of Analyst Coverage
Inovio Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
98.99% of the outstanding shares of Inovio Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Inovio Pharmaceuticals has a short interest ratio ("days to cover") of 6.3.
Change versus previous month
Short interest in Inovio Pharmaceuticals has recently decreased by 5.78%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Inovio Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Inovio Pharmaceuticals does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Inovio Pharmaceuticals has received a 70.39% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for infectious diseases", "Clinical research services for cancer", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Inovio Pharmaceuticals is -0.84.

1.9

News and Social Media Coverage

News Sentiment
Inovio Pharmaceuticals has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Inovio Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
Only 7 people have searched for INO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 14 people have added Inovio Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -7% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Inovio Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.90% of the stock of Inovio Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 26.79% of the stock of Inovio Pharmaceuticals is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Inovio Pharmaceuticals are expected to grow in the coming year, from ($5.80) to ($3.89) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Inovio Pharmaceuticals is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Inovio Pharmaceuticals is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Inovio Pharmaceuticals has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Inovio Pharmaceuticals Stock (NASDAQ:INO)

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

INO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

INO Stock News Headlines

February 10, 2024 | americanbankingnews.com

Inovio Pharmaceuticals (NASDAQ:INO) Stock Price Passes Above 200 Day Moving Average of $5.55

February 5, 2024 | msn.com

Penn’s BRCA cancer vaccine trial aims to prevent the disease in healthy people

February 12, 2024 | Edge On The Street (Ad)

An Unusual Way to Invest in Gold

Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.

February 4, 2024 | americanbankingnews.com

Inovio Pharmaceuticals (NASDAQ:INO) Rating Lowered to Sell at StockNews.com

February 2, 2024 | finanznachrichten.de

INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan

January 30, 2024 | finance.yahoo.com

How Much Upside is Left in Inovio (INO)? Wall Street Analysts Think 223.72%

January 28, 2024 | uk.investing.com

Inovio Pharmaceuticals Inc (0A43)

January 25, 2024 | msn.com

Inovio upgraded at Oppenheimer on rare disease therapy

February 12, 2024 | The Freeport Society (Ad)

Obama’s 2024 Confession

Barack Obama’s confession about the 2024 election just leaked online… In short, he’s worried Biden “could very well lose.” But before you think that means Trump will win… You should see the evidence I’ve found about an election shock that could come as soon as August 19th.

January 24, 2024 | investorplace.com

Why Is Inovio Pharmaceuticals (INO) Stock Down Today?

January 23, 2024 | finanznachrichten.de

INOVIO Pharmaceuticals, Inc.: INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split

January 23, 2024 | finance.yahoo.com

INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split

January 12, 2024 | finance.yahoo.com

Inovio Pharma (INO) Stock Rallies 134% in a Month: Here's Why

January 4, 2024 | msn.com

JMP Securities Initiates Coverage of Inovio Pharmaceuticals (INO) with Market Outperform Recommendation

January 3, 2024 | markets.businessinsider.com

INOVIO Plans To Submit BLA For INO-3107 In H2 - Quick Facts

January 3, 2024 | finance.yahoo.com

INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program

November 22, 2023 | finance.yahoo.com

The 3 Most Undervalued Biotech Stocks to Buy: November 2023

November 10, 2023 | finance.yahoo.com

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2023 Earnings Call Transcript

November 10, 2023 | finanznachrichten.de

INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights

November 10, 2023 | finance.yahoo.com

Q3 2023 Inovio Pharmaceuticals Inc Earnings Call

November 10, 2023 | finance.yahoo.com

Inovio Pharmaceuticals (INO) Q3 2023 Earnings Call Transcript

November 9, 2023 | msn.com

Inovio files for $300M mixed shelf

November 9, 2023 | markets.businessinsider.com

Inovio Pharmaceuticals Inc. Q3 loss drops in line with estimates

November 9, 2023 | finance.yahoo.com

INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights

October 26, 2023 | finance.yahoo.com

INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023

October 19, 2023 | finance.yahoo.com

Inovio Pharma (INO) Stock Surges 19% This Month: Here's Why

October 11, 2023 | benzinga.com

Inovio Stock Continues To Surge: What's Going On?

See More Headlines

Receive INO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/09/2023
Today: 2/12/2024
Next Earnings (Estimated): 3/06/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:INO
CUSIP: N/A
CIK: 1055726
Web: www.inovio.com
Phone: (267) 440-4200
Fax: 267-440-4242
Employees: 184
Year Founded: 1979

Price Target and Rating

Average Stock Price Target: $13.33
High Stock Price Target: $24.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +97.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($7.5630)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-279,820,000.00
Net Margins: -19,271.31%
Pretax Margin: -19,271.31%
Return on Equity: -84.52%
Return on Assets: -59.18%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.00
Quick Ratio: 4.00

Sales & Book Value

Annual Sales: $10.26 million
Price / Sales: 14.94
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $10.70 per share
Price / Book: 0.63

Miscellaneous

Outstanding Shares: 22,740,000
Free Float: 22,308,000
Market Cap: $153.27 million
Optionable: Optionable
Beta: 0.87

Social Links

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Jacqueline E. Shea Ph.D. (Age 58)
CEO, President & Director
Comp: $1.08M
Mr. Peter D. Kies (Age 61)
Chief Financial Officer
Comp: $688.72k
Dr. Laurent M. Humeau Ph.D. (Age 57)
Chief Scientific Officer
Comp: $673.59k
Thomas Hong
Manager of Investor Relations
Mr. Robert L. Crotty J.D. (Age 50)
General Counsel & Chief Compliance Officer
Mr. E. J. Brandreth MBA
Senior Vice President of Quality Assurance
Dr. Jeffrey Skolnik
Senior Vice President of Clinical Development
Mr. Robert J. Juba Jr.
Senior Vice President of Biological Manufacturing & Clinical Supply Management
Mr. Stephen Kemmerrer M.B.A.
P.E., Senior Vice President of Engineering Development
Mr. Shawn D. Bridy M.A.
M.B.A., Senior Vice President of Business Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INO Stock Analysis - Frequently Asked Questions

Should I buy or sell Inovio Pharmaceuticals stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" INO shares.
View INO analyst ratings or view top-rated stocks.
What is Inovio Pharmaceuticals' stock price target for 2024?: 3 Wall Street research analysts have issued 1-year price targets for Inovio Pharmaceuticals' stock. Their INO share price targets range from $4.00 to $24.00. On average, they anticipate the company's share price to reach $13.33 in the next twelve months. This suggests a possible upside of 97.8% from the stock's current price.
View analysts price targets for INO or view top-rated stocks among Wall Street analysts.
How have INO shares performed in 2024?: Inovio Pharmaceuticals' stock was trading at $6.12 at the beginning of 2024. Since then, INO stock has increased by 10.1% and is now trading at $6.74.
View the best growth stocks for 2024 here.
When is Inovio Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our INO earnings forecast.
How were Inovio Pharmaceuticals' earnings last quarter?: Inovio Pharmaceuticals, Inc. (NASDAQ:INO) released its quarterly earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, beating the consensus estimate of ($1.68) by $0.12. The biopharmaceutical company had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.20 million. Inovio Pharmaceuticals had a negative trailing twelve-month return on equity of 84.52% and a negative net margin of 19,271.31%. During the same period in the previous year, the business posted ($5.52) earnings per share.
When did Inovio Pharmaceuticals' stock split?: Inovio Pharmaceuticals's stock reverse split before market open on Thursday, January 25th 2024. The 1-12 reverse split was announced on Thursday, January 25th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is J. Joseph Kim's approval rating as Inovio Pharmaceuticals' CEO?: 12 employees have rated Inovio Pharmaceuticals Chief Executive Officer J. Joseph Kim on Glassdoor.com. J. Joseph Kim has an approval rating of 82% among the company's employees.
What other stocks do shareholders of Inovio Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX), Moderna (MRNA), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).
Who are Inovio Pharmaceuticals' major shareholders?: Inovio Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Green Alpha Advisors LLC (0.17%), Keystone Financial Group (0.54%), Vanguard Personalized Indexing Management LLC (0.51%), Principal Financial Group Inc. (0.30%), Simplex Trading LLC (0.00%) and Wolverine Asset Management LLC (0.00%). Insiders that own company stock include David B Weiner, David B Weiner, Jacqueline Elizabeth Shea, Laurent Humeau, Lota S Zoth, Peter Kies and Simon X Benito.
View institutional ownership trends.
How do I buy shares of Inovio Pharmaceuticals?: Shares of INO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INO) was last updated on 2/12/2024 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Inovio Pharmaceuticals (INO) Stock Price, News & Analysis

Inovio Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Inovio Pharmaceuticals Stock (NASDAQ:INO)

INO Stock Price History

INO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

INO Stock Analysis - Frequently Asked Questions

Overall MarketRank^™